{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:01Z","timestamp":1794047461589,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Osteolytic bone lesion is a major cause of lower quality of life and poor prognosis in patients with multiple myeloma (MM), but molecular pathogenesis of the osteolytic process in MM remains elusive. Fms-like tyrosine kinase 3 ligand (FLT3L) was reported to be elevated in bone marrow (BM) and blood of patients with advanced MM who often show osteolysis. Here, we investigated a functional link of FLT3L to osteolytic process in MM. We recruited 86, 306, and 52 patients with MM, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL), respectively. FLT3L levels of patients with hematologic malignancies were measured in BM-derived plasma and found to be significantly higher in MM than in AML or ALL, which rarely show osteolysis. FLT3L levels were further elevated in MM patients with bone lesion compared with patients without bone lesion. In vitro cell-based assays showed that the administration of FLT3L to HEK293T, HeLa, and U2OS cells led to an increase in the DKK1 transcript level through STAT3 phosphorylation at tyrosine 705. WNT reporter assay showed that FLT3L treatment reduced WNT signaling and nuclear translocation of \u03b2-catenin. These results collectively show that the FLT3L-STAT3-DKK1 pathway inhibits WNT signaling-mediated bone formation in MM, which can cause osteolytic bone lesion. Finally, transcriptomic profiles revealed that FLT3L and DKK1 were predominantly elevated in the hyperdiploidy subtype of MM. Taken together, FLT3L can serve as a promising biomarker for predicting osteolytic bone lesion and also a potential therapeutic target to prohibit the progression of the osteolytic process in MM with hyperdiploidy.<\/jats:p>","DOI":"10.3324\/haematol.2023.283784","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:26:16Z","timestamp":1704943576000},"page":"2207-2218","source":"Crossref","is-referenced-by-count":4,"title":["Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Dongyeop","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongchan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chansu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Sung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"63419","doi-asserted-by":"crossref","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018; 101(2):237-244.","DOI":"10.1111\/ejh.13083"},{"key":"63420","doi-asserted-by":"crossref","unstructured":"Sneyd MJ, Gray AR, Morison IM. Trends in survival from myeloma, 1990-2015: a competing risks analysis. BMC Cancer. 2021; 21(1):821.","DOI":"10.1186\/s12885-021-08544-7"},{"key":"63421","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014; 25(1):195-200.","DOI":"10.1093\/annonc\/mdt483"},{"key":"63422","doi-asserted-by":"crossref","unstructured":"Denaro V, Denaro L, Albo E, Papapietro N, Piccioli A, Di Martino A. Surgical management of spinal fractures and neurological involvement in patients with myeloma. Injury. 2016; 47(Suppl 4):S49-S53.","DOI":"10.1016\/j.injury.2016.07.047"},{"key":"63423","doi-asserted-by":"crossref","unstructured":"Body JJ, Pereira J, Sleeboom H. Health resource utilization associated with skeletal-related events: results from a retrospective European study. Eur J Health Econ. 2016; 17(6):711-721.","DOI":"10.1007\/s10198-015-0716-7"},{"key":"63424","doi-asserted-by":"crossref","unstructured":"Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data. J Bone Oncol. 2019; 14:100215.","DOI":"10.1016\/j.jbo.2018.100215"},{"key":"63425","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-2869.","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"63426","doi-asserted-by":"crossref","unstructured":"Morgan GJ, Davies FE, Gregory WM. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013; 19(21):6030-6038.","DOI":"10.1158\/1078-0432.CCR-12-3211"},{"key":"63427","doi-asserted-by":"crossref","unstructured":"Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm. 2017; 2017:1852517.","DOI":"10.1155\/2017\/1852517"},{"key":"63428","doi-asserted-by":"crossref","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018; 8(1):7.","DOI":"10.1038\/s41408-017-0037-4"},{"key":"63429","doi-asserted-by":"crossref","unstructured":"Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res. 2011; 17(6):1278-1286.","DOI":"10.1158\/1078-0432.CCR-10-1804"},{"key":"63430","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-2494.","DOI":"10.1056\/NEJMoa030847"},{"key":"63431","doi-asserted-by":"crossref","unstructured":"Dun X, Jiang H, Zou J. Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma. Mol Cancer. 2010; 9:247.","DOI":"10.1186\/1476-4598-9-247"},{"key":"63432","unstructured":"Yuan Y, Guo M, Gu C, Yang Y. The role of Wnt\/\u03b2-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). Am J Transl Res. 2021; 13(9):9932-9949."},{"key":"63433","doi-asserted-by":"crossref","unstructured":"Glass DA 2nd, Bialek P, Ahn JD. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8(5):751-764.","DOI":"10.1016\/j.devcel.2005.02.017"},{"key":"63434","doi-asserted-by":"crossref","unstructured":"van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019; 33(5):1063-1075.","DOI":"10.1038\/s41375-019-0404-1"},{"key":"63435","doi-asserted-by":"crossref","unstructured":"Politou MC, Heath DJ, Rahemtulla A. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006; 119(7):1728-1731.","DOI":"10.1002\/ijc.22033"},{"key":"63436","doi-asserted-by":"crossref","unstructured":"Yu F, Yu C, Li F. Wnt\/\u03b2-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021; 6(1):307.","DOI":"10.1038\/s41392-021-00701-5"},{"key":"63437","doi-asserted-by":"crossref","unstructured":"Steiner N, Hajek R, Sevcikova S. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLoS One. 2017; 12(7):e0181487.","DOI":"10.1371\/journal.pone.0181487"},{"key":"63438","doi-asserted-by":"crossref","unstructured":"Kokonozaki M, Kanellou P, Pappa CA. Serum levels of soluble FLT3 ligand in patients with active multiple myeloma constitute marker of bone marrow plasma cell proliferative activity. Crit Rev Oncog. 2017; 22(3-4):255-262.","DOI":"10.1615\/CritRevOncog.2018021355"},{"key":"63439","doi-asserted-by":"crossref","unstructured":"Anandasabapathy N, Breton G, Hurley A. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015; 50(7):924-930.","DOI":"10.1038\/bmt.2015.74"},{"key":"63440","doi-asserted-by":"crossref","unstructured":"Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel). 2021; 13(9):2018.","DOI":"10.3390\/cancers13092018"},{"key":"63441","doi-asserted-by":"crossref","unstructured":"Hayakawa F, Sugimoto K, Harada Y. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 2013; 3(11):e166.","DOI":"10.1038\/bcj.2013.63"},{"key":"63442","doi-asserted-by":"crossref","unstructured":"Ch\u00e9rel M, Gouard S, Gaschet J. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med. 2013; 54(9):1597-1604.","DOI":"10.2967\/jnumed.112.111997"},{"key":"63443","doi-asserted-by":"crossref","unstructured":"Cho H. Diagnosis and management of monoclonal gammopathy of clinical significance. Blood Res. 2022; 57(S1):20-26.","DOI":"10.5045\/br.2022.2022035"},{"key":"63444","doi-asserted-by":"crossref","unstructured":"Zheng R, Levis M, Piloto O. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004; 103(1):267-274.","DOI":"10.1182\/blood-2003-06-1969"},{"key":"63445","doi-asserted-by":"crossref","unstructured":"Zhou J, Bi C, Janakakumara JV. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009; 113(17):4052-4062.","DOI":"10.1182\/blood-2008-05-156422"},{"key":"63446","doi-asserted-by":"crossref","unstructured":"Berenson JR, Lichtenstein A, Porter L. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996; 334(8):488-493.","DOI":"10.1056\/NEJM199602223340802"},{"key":"63447","doi-asserted-by":"crossref","unstructured":"Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003; 19(6):903-912.","DOI":"10.1016\/S1074-7613(03)00332-7"},{"key":"63448","doi-asserted-by":"crossref","unstructured":"Chauvistr\u00e9 H, K\u00fcstermann C, Rehage N. Dendritic cell development requires histone deacetylase activity. Eur J Immunol. 2014; 44(8):2478-2488.","DOI":"10.1002\/eji.201344150"},{"key":"63449","doi-asserted-by":"crossref","unstructured":"Kamburov A, Wierling C, Lehrach H, Herwig R. ConsensusPathDB--a database for integrating human functional interaction networks. Nucleic Acids Res. 2009; 37(Database issue):D623-628.","DOI":"10.1093\/nar\/gkn698"},{"key":"63450","doi-asserted-by":"crossref","unstructured":"Gau YC, Yeh TJ, Hsu CM, Hsiao SY, Hsiao HH. Pathogenesis and treatment of myeloma-related bone disease. Int J Mol Sci. 2022; 23(6):3112.","DOI":"10.3390\/ijms23063112"},{"key":"63451","doi-asserted-by":"crossref","unstructured":"Liu Z, Liu H, Li Y. Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma. Int J Mol Med. 2020; 45(4):1112-1120.","DOI":"10.3892\/ijmm.2020.4475"},{"key":"63452","unstructured":"Liu H, He J, Yang J. Tumor cell p38 MAPK: a trigger of cancer bone osteolysis. Cancer Cell Microenviron. 2015; 2(1):e464."},{"key":"63453","doi-asserted-by":"crossref","unstructured":"Beiter K, Hiendlmeyer E, Brabletz T. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene. 2005; 24(55):8200-8204.","DOI":"10.1038\/sj.onc.1208960"},{"key":"63454","doi-asserted-by":"crossref","unstructured":"Zhou R, Yuan Z, Liu J, Liu J. Calcitonin gene-related peptide promotes the expression of osteoblastic genes and activates the WNT signal transduction pathway in bone marrow stromal stem cells. Mol Med Rep. 2016; 13(6):4689-4696.","DOI":"10.3892\/mmr.2016.5117"},{"key":"63455","doi-asserted-by":"crossref","unstructured":"Bonnet N, Brun J, Rousseau JC, Duong LT, Ferrari SL. Cathepsin K controls cortical bone formation by degrading periostin. J Bone Miner Res. 2017; 32(7):1432-1441.","DOI":"10.1002\/jbmr.3136"},{"key":"63456","doi-asserted-by":"crossref","unstructured":"Zhu B, Xue F, Li G, Zhang C. CRYAB promotes osteogenic differentiation of human bone marrow stem cells via stabilizing \u03b2-catenin and promoting the Wnt signalling. Cell Prolif. 2020; 53(1):e12709.","DOI":"10.1111\/cpr.12709"},{"key":"63457","doi-asserted-by":"crossref","unstructured":"Chng WJ, Kumar S, Vanwier S. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007; 67(7):2982-2989.","DOI":"10.1158\/0008-5472.CAN-06-4046"},{"key":"63458","doi-asserted-by":"crossref","unstructured":"Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001; 98(7):2229-2238.","DOI":"10.1182\/blood.V98.7.2229"},{"key":"63459","doi-asserted-by":"crossref","unstructured":"Weinhold N, Kirn D, Seckinger A. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016; 101(3):e116-119.","DOI":"10.3324\/haematol.2015.136929"},{"key":"63460","doi-asserted-by":"crossref","unstructured":"Chretien ML, Corre J, Lauwers-Cances V. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. Blood. 2015; 126(25):2713-2719.","DOI":"10.1182\/blood-2015-06-650242"},{"key":"63461","doi-asserted-by":"crossref","unstructured":"Musto P, Petrucci MT, Bringhen S. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008; 113(7):1588-1595.","DOI":"10.1002\/cncr.23783"},{"key":"63462","doi-asserted-by":"crossref","unstructured":"Raje N, Woo SB, Hande K. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008; 14(8):2387-2395.","DOI":"10.1158\/1078-0432.CCR-07-1430"},{"key":"63463","doi-asserted-by":"crossref","unstructured":"Park-Wyllie LY, Mamdani MM, Juurlink DN. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305(8):783-789.","DOI":"10.1001\/jama.2011.190"},{"key":"63464","doi-asserted-by":"crossref","unstructured":"Raje N, Terpos E, Willenbacher W. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, doubledummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018; 19(3):370-381.","DOI":"10.1016\/S1470-2045(18)30072-X"},{"key":"63465","doi-asserted-by":"crossref","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017; 317(1):48-58.","DOI":"10.1001\/jama.2016.19425"},{"key":"63466","doi-asserted-by":"crossref","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020; 13(1):155.","DOI":"10.1186\/s13045-020-00992-1"},{"key":"63467","doi-asserted-by":"crossref","unstructured":"Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 2008; 42(4):669-680.","DOI":"10.1016\/j.bone.2007.12.006"},{"key":"63468","doi-asserted-by":"crossref","unstructured":"Zhan F, Huang Y, Colla S. The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-2028.","DOI":"10.1182\/blood-2005-11-013458"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283784\/76492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283784\/77191","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11402\/76492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:31Z","timestamp":1794045931000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283784","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}